Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00239187 | A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1 | PHASE1 | COMPLETED | 30 | — | — | Sep 1, 2005 | Jan 1, 2007 | Oct 18, 2019 | 3 | United States |
| Name | Type | Description |
|---|---|---|
| E1 and G1 | DRUG | - |
Inclusion Criteria: * Informed consent obtained from participants * Clinical diagnosis Type 2 diabetes requiring treatment with Metformin and/or TZD and who are otherwise healthy * On a stable Metformin and/or TZD regimen for at least 60 days prior to screening * Maximum stimulated c-peptide level ...